Feasibility of detecting atrophy relevant for disability and cognition in multiple sclerosis using 3D-FLAIR.

"Declarations Conflicts of interestS. Noteboom is supported by research grants from Atara Biotherapeutics, Merck and Biogen. D. R. van Nederpelt has nothing to disclose. A. Bajrami has nothing to disclose. B. Moraal has nothing to disclose. M. W. A. Caan is shareholder of Nico.lab International Ltd. F. Barkhof serves on the steering committee or iDMC member for Biogen, Merck, Roche, EISAI and Prothena. Consultant for Roche, Biogen, Merck, IXICO, Jansen, Combinostics. Research agreements with Merck, Biogen, GE Healthcare, Roche. Co-founder and shareholder of Queen Square Analytics LTD. Supported by the NIHR biomedical research center at UCLH. M. Calabrese was supported by the GR-2013-02-355322 grant from Italian Ministry of Health as well as the progressive MS alliance and reports grants and personal fees from Biogen Idec, Merck Serono, Novartis, and Roche. H. Vrenken has received research grants from Pfizer, Merck Serono, Novartis, and Teva, speaker honoraria from Novartis, and consulting fees from Merck Serono; all funds were paid directly to his institution. E. M. M. Strijbis has nothing to disclose. M.D. Steenwijk is supported by research grants from Atara Biotherapeutics, Merck and Biogen. M.M. Schoonheim serves on the editorial board of Neurology and Frontiers in Neurology, receives research support from the Dutch MS Research Foundation, Eurostars-EUREKA, ARSEP, Amsterdam Neuroscience, MAGNIMS and ZonMW (VIDI Grant 09150172010056) and has served as a consultant for or received research support from Atara Biotherapeutics, Biogen, Celgene/Bristol Meyers Squibb, Genzyme, MedDay and Merck. Conflicts of interest S. Noteboom is supported by research grants from Atara Biotherapeutics, Merck and Biogen. D. R. van Nederpelt has nothing to disclose. A. Bajrami has nothing to disclose. B. Moraal has nothing to disclose. M. W. A. Caan is shareholder of Nico.lab International Ltd. F. Barkhof serves on the steering committee or iDMC member for Biogen, Merck, Roche, EISAI and Prothena. Consultant for Roche, Biogen, Merck, IXICO, Jansen, Combinostics. Research agreements with Merck, Biogen, GE Healthcare, Roche. Co-founder and shareholder of Queen Square Analytics LTD. Supported by the NIHR biomedical research center at UCLH. M. Calabrese was supported by the GR-2013-02-355322 grant from Italian Ministry of Health as well as the progressive MS alliance and reports grants and personal fees from Biogen Idec, Merck Serono, Novartis, and Roche. H. Vrenken has received research grants from Pfizer, Merck Serono, Novartis, and Teva, speaker honoraria from Novartis, and consulting fees from Merck Serono; all funds were paid directly to his institution. E. M. M. Strijbis has nothing to disclose. M.D. Steenwijk is supported by research grants from Atara Biotherapeutics, Merck and Biogen. M.M. Schoonheim serves on the editorial board of Neurology and Frontiers in Neurology, receives research support from the Dutch MS Research Foundation, Eurostars-EUREKA, ARSEP, Amsterdam Neuroscience, MAGNIMS and ZonMW (VIDI Grant 09150172010056) and has served as a consultant for or received research support from Atara Biotherapeutics, Biogen, Celgene/Bristol Meyers Squibb, Genzyme, MedDay and Merck."

"Funding This project is supported by research Grants from ZonMW (VIDI Grant 09150172010056) and the Dutch MS Research Foundation (08-650, 13-820 and 14-358)."